Clinical trials: Thalidomide
Pain, Chronic, Pain
Understanding and Managing Pain for Thalidomide Survivors
Aim: To explore the pain experience of Thalidomide survivors and propose an effective pain management service, tailored to meet the unique needs of this population.
- Trial name
- TRIUMPH-TS (NCT06398132)
- Testing
- Usual Care
- Where
- United Kingdom
- Volunteers
- 73 people
- Sponsor
- University of Nottingham
Multiple Myeloma
Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
This is an international multi-center prospective, double randomized, open, controlled phase III study with a phase II entrance phase to compare the therapeutic efficacy of thalidomide plus dexamethasone to conventional melphalan…
- Trial name
- NCT00205751
- Testing
- Thalidomide/Dexamethasone vs Melphalan/Prednisone
- Where
- Austria
- Volunteers
- 350 people
- Sponsor
- Austrian Forum Against Cancer
Mantle Cell Lymphoma (MCL)
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
For relapsed/refractory mantle cell lymphoma patients that previously treated with BTK inhibitors: The first part involves 6 cycles of combined therapy with zuberitamab, selinexor, dexamethasone, and thalidomide.
- Trial name
- NCT07264894
- Testing
- ZSDT regimen
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhengzhou University
Multiple Myeloma
Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma
The purpose of this study is to determine whether lower than conventional doses of dexamethasone and thalidomide; and a higher dosing frequency of zoledronic acid are effective in the treatment of newly-diagnosed multiple myeloma.
- Trial name
- dtZ (NCT00263484)
- Testing
- dexamethasone, thalidomide, zoledronic acid
- Where
- 10 sites in India, Singapore and 1 more
- Volunteers
- 56 people
- Sponsor
- Gleneagles Hospital
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
Study of VTD in Waldenstrom's Macroglobulinemia
This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed Waldenstrom's…
- Trial name
- BOMB-THROW (NCT03335098)
- Testing
- Bortezomib
- Where
- 2 sites in South Korea
- Volunteers
- 15 people
- Sponsor
- Seoul National University Hospital
Multiple Myeloma
Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients
This study will evaluate the safety and the efficacy of the association of Melphalan/ Prednisone/Thalidomide/Defibrotide (MPTD) as salvage treatment in advanced and refractory myeloma patients.
- Trial name
- MPTD (NCT00406978)
- Testing
- Prednisone, Melphalan, Thalidomide
- Where
- 5 sites in Italy
- Volunteers
- 24 people
- Sponsor
- Silvio Aime
Multiple Myeloma
Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years
This protocol is an international, multicenter, comparative, open and randomized study designed to compare the safety and efficacy (in terms of response rate) from three induction chemotherapy schemes…
- Trial name
- NCT01532856
- Testing
- Thalidomide, Cyclophosphamide, Dexamethasone, Thalidomide, Dexamethasone, Thalidomide, Melphalan, Prednisone
- Where
- 3 sites in Brazil
- Volunteers
- 64 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Endometrial Cancer, Sarcoma
Thalidomide in Treating Patients With Gynecologic Sarcomas
RATIONALE: Thalidomide may stop the growth of gynecologic sarcomas by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent…
- Trial name
- NCT00006005
- Testing
- thalidomide
- Where
- 10 sites in United States
- Sponsor
- New York University Cancer Institute
Carcinoma, Hepatocellular
Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.
- Trial name
- NCT00225290
- Testing
- Thalidomide(Thado)
- Where
- Taiwan
- Volunteers
- 230 people
- Sponsor
- TTY Biopharm
Hepatocellular Carcinoma, Recurrence
Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma
Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection. To date, adjuvant chemotherapy or other adjuvant modalities have not been proven effective in preventing or delaying…
- Trial name
- NCT01924624
- Testing
- Thalidomide
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as…
- Conditions
- Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis
- Trial name
- NCT01849783
- Testing
- dexamethasone, cisplatin, doxorubicin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Margarida Magalhaes-Silverman
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer.
- Trial name
- NCT00028886
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 17 sites in Belgium, Netherlands
- Volunteers
- 450 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Multiple Myeloma
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant.
- Trial name
- NCT00075829
- Testing
- One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant
- Where
- 36 sites in United States
- Volunteers
- 710 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. Prednisone may be effective in preventing relapse of multiple myeloma.
- Trial name
- NCT00006890
- Testing
- prednisone, thalidomide
- Where
- 64 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- NCIC Clinical Trials Group
Multiple Myeloma
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
The marked activity of thalidomide (thal) and dexamethasone (dex) in relapsed and refractory multiple myeloma (MM) provided the basis for this phase 2 clinical study aimed at investigating the efficacy and toxicity of thal-dex…
- Trial name
- NCT01341262
- Testing
- Thalidomide, Dexamethasone, Zoledronic acid
- Volunteers
- 378 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Recurrent Melanoma, Stage IV Melanoma
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
This phase II trial is studying how well giving temozolomide together with thalidomide works in treating patients with brain metastases secondary to melanoma.
- Conditions
- Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
- Trial name
- NCT00072163
- Testing
- temozolomide, thalidomide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.
- Trial name
- BDHCLL001 (NCT03980002)
- Testing
- FCR and Ibrutinib, BR and Ibrutinib, Ibrutinib and Thalidomide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Intraocular Melanoma, Melanoma (Skin)
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of melanoma by stopping blood flow to the tumor.
- Trial name
- NCT00005815
- Testing
- temozolomide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
The purpose of this phase I study is to determine the maximal tolerable dose (MTD) of thalidomide (THADO®) in combination with fixed dose of sorafenib (NEXAVAR®) for the treatment of advanced or metastatic HCC.
- Trial name
- NCT00971126
- Testing
- sorafenib (Nexavar®), thalidomide (Thado®)
- Where
- Taiwan
- Volunteers
- 3 people
- Sponsor
- National Health Research Institutes, Taiwan
Gastrointestinal Vascular Malformation
the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation
Gastrointestinal vascular malformation (GIVM), which is an important cause of acute or chronic gastrointestinal bleeding, currently lacks of effective treatment.
- Trial name
- NCT02707484
- Testing
- Thalidomide (100mg), Thalidomide (50mg)
- Where
- 10 sites in China
- Volunteers
- 150 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine